Last reviewed: June 25, 2026

Last updated: June 25, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide, the active compound in Wegovy, produced average weight loss of 14.9% in pivotal clinical trials—a result that fundamentally shifts how medicine approaches sustainable body weight management. PlexusDx delivers compounded semaglutide injections starting at just $149 per month, making this proven therapy accessible without insurance barriers. Understanding realistic weight loss timelines, individual variability, and personalized response factors helps you set evidence-based expectations for your transformation journey.

Clinical Trial Weight Loss Data for Semaglutide Therapy

The STEP trials, which evaluated semaglutide across multiple dose levels, demonstrated that participants achieved mean weight reductions of 9.2-14.9% after 68 weeks of treatment. These landmark studies included over 4,500 adults with obesity or overweight status, providing robust real-world applicability data for typical patient populations. Notably, higher maintenance doses (2.4 mg weekly) produced the greatest weight loss, with approximately 86% of participants achieving clinically meaningful reductions of at least 5% body weight.

Individual trial participants experienced weight loss trajectories that accelerated during dose escalation phases and continued through maintenance periods. The trial protocol included weekly injections combined with behavioral counseling, nutritional support, and exercise guidance—components that significantly enhanced overall outcomes. Importantly, weight loss continued to accrue throughout the 68-week observation window, with many participants reporting the most substantial changes in months 4-8 after treatment initiation.

Timeline of Weight Loss: Week-by-Week Expectations

Most patients begin noticing appetite suppression within the first 2-3 weeks of semaglutide therapy, though measurable weight loss typically emerges around week 4-6 as dietary intake naturally decreases. Initial weight reductions often range from 2-4 pounds monthly during the dose titration phase, when injections increase from 0.25 mg to 2.4 mg over 16 weeks. This gradual escalation strategy minimizes gastrointestinal side effects while allowing your body to physiologically adapt to the medication's mechanisms.

The most dramatic weight loss acceleration occurs between weeks 8-24, when most patients reach therapeutic doses and establish consistent injection routines. During this window, monthly weight loss often reaches 4-8 pounds as appetite suppression peaks and metabolic efficiency improves. By month 6, many patients have achieved 10-15% of their initial body weight loss, with continued gradual reductions occurring through months 7-12 as the body reaches a new metabolic equilibrium.

Factors That Influence Individual Weight Loss Variability

Genetic predisposition plays a measurable role in how your body responds to semaglutide therapy, with variations in GLP-1 receptor sensitivity, appetite-regulation pathways, and fat metabolism significantly affecting outcomes. The PlexusDx Precision Peptide Genetic Test identifies key variants including GLP1R rs6923761, MC4R rs17782313, and FTO rs9939609—genetic insights that map how your 14 major metabolic pathways respond to GLP-1 medication. Understanding your genetic profile helps predict whether you'll experience faster satiety onset, greater appetite reduction intensity, or enhanced weight loss velocity during treatment.

Beyond genetics, baseline body weight, age, insulin resistance status, and pre-existing metabolic health conditions significantly impact weight loss rate and total achievable weight reduction. Patients with higher starting body weights often experience faster initial reductions in absolute pounds, though percentage-based weight loss remains comparable across populations. Lifestyle factors including sleep quality, stress management, physical activity levels, and dietary macronutrient composition fundamentally amplify medication effectiveness—semaglutide works synergistically with behavioral changes rather than independently.

PlexusDx Compounded Semaglutide: Accessible Weight Loss Without Markup Costs

PlexusDx delivers pharmaceutical-grade semaglutide from licensed 503A compounding pharmacies to all 50 states, eliminating the high retail pricing of brand-name Wegovy while maintaining identical active ingredients and therapeutic efficacy. Compounded semaglutide injections start at just $149 per month—a flat rate that never increases with dose escalation, ensuring your price remains stable as your dose rises through the standard titration protocol. No insurance requirement, no membership fees, and HSA/FSA eligibility combine to make clinical-grade semaglutide therapy genuinely accessible for weight management transformation.

Each PlexusDx prescription arrives with detailed injection instructions, sterile supplies, and comprehensive dosing guidance aligned with clinical best practices and FDA-approved semaglutide dosing schedules. Optional add-on genetic testing through the Precision Peptide Genetic Test ($99 after your first treatment month) reveals your individual metabolic response profile, enabling personalized treatment optimization and realistic expectation-setting for your specific weight loss trajectory. PlexusDx serves patients regardless of prior insurance denials or Wegovy eligibility determinations, democratizing access to evidence-based GLP-1 therapy nationwide.

Sustaining Weight Loss: What Happens After Reaching Your Goal

Maintenance of semaglutide-achieved weight loss requires continued medication use, as clinical evidence demonstrates that weight typically returns when treatment discontinues—a pattern reflecting the medication's physiological mechanism of appetite regulation rather than indicating failed outcomes. Many patients maintain their results indefinitely by continuing semaglutide injections at therapeutic doses, with long-term safety data from multi-year observational studies supporting this approach. Combining semaglutide therapy with sustained lifestyle modifications, including exercise routines and dietary awareness, significantly enhances long-term weight stability and reduces regain risk.

PlexusDx allows flexible, long-term treatment continuation at consistent $149 monthly pricing, eliminating financial barriers that might otherwise force discontinuation during maintenance phases. Patients who establish consistent injection routines, incorporate regular physical activity, and maintain mindful eating patterns consistently report the best long-term outcomes and greatest satisfaction with their weight management transformation. Regular check-ins with qualified providers help monitor your continued response and optimize your regimen throughout your semaglutide therapy journey.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How much weight can I realistically lose using semaglutide injections?

Clinical trials demonstrate that semaglutide users lose 9.2-14.9% of body weight over 68 weeks, with higher doses producing greater reductions. Individual results vary based on genetics, starting weight, lifestyle factors, and treatment adherence. PlexusDx compounded semaglutide delivers the same active ingredient as Wegovy at flat pricing starting at $149/mo.

When should I expect to see measurable weight loss results?

Most patients notice appetite suppression within 2-3 weeks of starting semaglutide, with measurable weight loss typically beginning around week 4-6 of treatment. The most substantial weight loss usually occurs during months 2-6 as your dose reaches therapeutic levels and your body adapts to the medication's appetite-suppressing effects.

Does PlexusDx compounded semaglutide work the same as brand-name Wegovy?

Yes—PlexusDx semaglutide injections contain the identical active pharmaceutical ingredient as Wegovy and are manufactured through licensed 503A compounding pharmacies meeting rigorous quality standards. The main difference is pricing: PlexusDx charges a flat $149/mo starting rate, whereas Wegovy typically costs $900-$1,300 monthly without insurance.

Are there genetic factors that affect how much weight I'll lose?

Absolutely. Your GLP1R gene variant (rs6923761), FTO gene status (rs9939609), and MC4R pathway sensitivity significantly influence appetite suppression intensity and metabolic response. The PlexusDx Precision Peptide Genetic Test ($99 add-on) identifies your genetic profile across 14 metabolic pathways and 150+ insights to predict your personalized weight loss potential.

What if I stop taking semaglutide—will I regain the weight?

Clinical evidence shows that most weight returns after discontinuing semaglutide, as the medication's primary mechanism involves appetite regulation rather than permanent metabolic change. Many patients maintain long-term results by continuing treatment indefinitely at PlexusDx's consistent $149/mo flat rate, combined with sustained lifestyle modifications and regular physical activity.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

learn